Activation of the PI3K effector protein kinase B following ligation of CD28 or Fas.
Parry
R
R
Department of Pharmacology, Bath University.
Smith
G
G
Reif
K
K
Sansom
D M
DM
Ward
S
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D018801:CD2 Antigens / Q000096:biosynthesis; D018106:CD28 Antigens / Q000096:biosynthesis / Q000276:immunology / Q000502:physiology*; D016466:CHO Cells; D006224:Cricetinae; D004789:Enzyme Activation; D006801:Humans; D019169:Jurkat Cells; D019869:Phosphatidylinositol 3-Kinases / Q000096:biosynthesis / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000378:metabolism; D014162:Transfection; D019014:fas Receptor / Q000276:immunology / Q000502:physiology*
D000911:Antibodies, Monoclonal; D018801:CD2 Antigens; D018106:CD28 Antigens; D019869:Phosphatidylinositol 3-Kinases; D017346:Protein Serine-Threonine Kinases; D011505:Protein-Tyrosine Kinases; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt; D011993:Recombinant Fusion Proteins; D019014:fas Receptor